Posted by Michael Wonder on 02 Oct 2019
Evolus receives approval for Nuceiva in the European Union
1 October 2019 - Evolus today announced that the European Commission has approved the marketing of Nuceiva (prabotulinumtoxinA).
Similar to other neurotoxins marketed in Europe, Nuceiva is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact in adults below 65 years of age.
The decision is applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein.
